Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial
Robert P. Giugliano,Christian T. Ruff,Stephen D. Wiviott,Francesco Nordio,Sabina A. Murphy,Johannes A.N. Kappelhof,Minggao Shi,Michele Mercuri,Elliott M. Antman,Eugene Braunwald +9 more
Reads0
Chats0
TLDR
Fewer total and cardiovascular deaths were observed with edoxaban as compared with warfarin in the ENGAGE AF-TIMI 48 trial, and this predominantly resulted from the significantly lower rate of major bleeding with Edoxaban.About:
This article is published in The American Journal of Medicine.The article was published on 2016-08-01 and is currently open access. It has received 55 citations till now. The article focuses on the topics: Edoxaban & Warfarin.read more
Citations
More filters
Journal ArticleDOI
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Jan Steffel,Peter Verhamme,Tatjana S. Potpara,Pierre Albaladejo,M Antz,Lien Desteghe,Karl Georg Haeusler,Jonas Oldgren,Holger Reinecke,Roldan-Schilling,Nigel Rowell,Peter Sinnaeve,Ronan Collins,Alan John Camm,Hein Heidbuchel +14 more
TL;DR: Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF) and have emerged as the preferred choice, particularly in patients newly started on antICOagulation.
Journal ArticleDOI
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
Jan Steffel,Ronan Collins,Matthias Antz,Pieter Cornu,Lien Desteghe,Karl Georg Haeusler,Jonas Oldgren,Holger Reinecke,Vanessa Roldan-Schilling,Nigel Rowell,Peter Sinnaeve,Thomas Vanassche,Tatjana S. Potpara,A. John Camm,Hein Heidbuchel,External reviewers,Gregory Y.H. Lip,Gregory Y.H. Lip,T. Deneke,Nikolaos Dagres,Giuseppe Boriani,Tze-Fan Chao,Eue Keun Choi,Mellanie True Hills,Itamar S. Santos,Deirdre A. Lane,Deirdre A. Lane,Dan Atar,Boyoung Joung,Oana Maria Cole,Mark Field +30 more
Journal ArticleDOI
Causes of Death in Anticoagulated Patients With Atrial Fibrillation.
Antonio Gómez-Outes,Julián Lagunar-Ruíz,Ana-Isabel Terleira-Fernández,Ana-Isabel Terleira-Fernández,Gonzalo Calvo-Rojas,Maria Luisa Suárez-Gea,Emilio Vargas-Castrillón,Emilio Vargas-Castrillón +7 more
TL;DR: In contemporary AF trials, most deaths were cardiac-related, whereas stroke and bleeding represented only a small subset of deaths, so interventions beyond anticoagulation are needed to further reduce mortality in AF.
Journal ArticleDOI
Causes of death in Japanese patients with atrial fibrillation: The Fushimi Atrial Fibrillation Registry.
Yoshimori An,Hisashi Ogawa,Yugo Yamashita,Mitsuru Ishii,Moritake Iguchi,Nobutoyo Masunaga,Masahiro Esato,Hikari Tsuji,Hiromichi Wada,Koji Hasegawa,Mitsuru Abe,Gregory Y.H. Lip,Gregory Y.H. Lip,Masaharu Akao +13 more
TL;DR: Non-CV death, mainly malignancy and infection, comprised more than a half of all deaths, which increased substantially in accordance with aging, in a Japanese community-based AF cohort.
Journal ArticleDOI
Left atrial structure and function and the risk of death or heart failure in atrial fibrillation.
Riccardo M. Inciardi,Robert P. Giugliano,Brian Claggett,Deepak K. Gupta,Alvin Chandra,Christian T. Ruff,Elliott M. Antman,Michele Mercuri,Michael A. Grosso,Eugene Braunwald,Scott D. Solomon,Engage Af-Timi Investigators +11 more
TL;DR: The present study aimed to assess the association between left atrial (LA) structure and function and the risk for cardiovascular death or heart failure hospitalization in a population with atrial fibrillation.
References
More filters
Journal ArticleDOI
Dabigatran versus warfarin in patients with atrial fibrillation
Stuart J. Connolly,Michael D. Ezekowitz,John W. Eikelboom,Jonas Oldgren,Amit Parekh,Janice Pogue,Paul A. Reilly,Ellison Themeles,Jeanne Varrone,Susan Wang,Marco Alings,Denis Xavier,Jun Zhu,Rafael Diaz,Basil S. Lewis,Harald Darius,Hans-Christoph Diener,Campbell D. Joyner,Lars Wallentin +18 more
TL;DR: In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.
Journal ArticleDOI
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel,Kenneth W. Mahaffey,Jyotsna Garg,Guohua Pan,Daniel E. Singer,Werner Hacke,Günter Breithardt,Jonathan L. Halperin,Graeme J. Hankey,Jonathan P. Piccini,Richard C. Becker,Christopher C. Nessel,John F. Paolini,Scott D. Berkowitz,Robert M. Califf +14 more
TL;DR: In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism and there was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivroxaban group.
Journal ArticleDOI
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger,John H. Alexander,Renato D. Lopes,Elaine M. Hylek,Michael G. Hanna,Hussein R. Al-Khalidi,Jack Ansell,Dan Atar,Alvaro Avezum,M. Cecilia Bahit,Rafael Diaz,J. Donald Easton,Justin A. Ezekowitz,Greg C. Flaker,David A. Garcia,Margarida Geraldes,Bernard J. Gersh,Sergey P. Golitsyn,Shinya Goto,Antonio G. Hermosillo,Stefan H. Hohnloser,John D. Horowitz,Puneet Mohan,Petr Jansky,Basil S. Lewis,Jose Lopez-Sendon,Prem Pais,Alexander Parkhomenko,Jun Zhu,Lars Wallentin +29 more
TL;DR: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.
Journal ArticleDOI
Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation
Brian F. Gage,Amy D. Waterman,William D. Shannon,Michael Boechler,Michael W. Rich,Martha J. Radford +5 more
TL;DR: The 2 existing classification schemes and especially a new stroke risk index, CHADS, can quantify risk of stroke for patients who have AF and may aid in selection of antithrombotic therapy.
Journal ArticleDOI
Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation
TL;DR: An updated meta-analysis of all currently available randomized trials that extends observations about the efficacy and safety of antithrombotic therapies for preventing stroke in patients who have atrial fibrillation is presented.
Related Papers (5)
Edoxaban versus warfarin in patients with atrial fibrillation
Robert P. Giugliano,Christian T. Ruff,Eugene Braunwald,Sabina A. Murphy,Stephen D. Wiviott,Jonathan L. Halperin,Albert L. Waldo,Michael D. Ezekowitz,Jeffrey I. Weitz,Witold Rużyłło,Mikhail Ruda,Yukihiro Koretsune,Joshua Betcher,Minggao Shi,Laura T. Grip,Laura T. Grip,Shirali P. Patel,Indravadan Patel,James J. Hanyok,Michele Mercuri,Elliott M. Antman,Elliott M. Antman,Abstr Act,Abstr Act +23 more
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger,John H. Alexander,Renato D. Lopes,Elaine M. Hylek,Michael G. Hanna,Hussein R. Al-Khalidi,Jack Ansell,Dan Atar,Alvaro Avezum,M. Cecilia Bahit,Rafael Diaz,J. Donald Easton,Justin A. Ezekowitz,Greg C. Flaker,David A. Garcia,Margarida Geraldes,Bernard J. Gersh,Sergey P. Golitsyn,Shinya Goto,Antonio G. Hermosillo,Stefan H. Hohnloser,John D. Horowitz,Puneet Mohan,Petr Jansky,Basil S. Lewis,Jose Lopez-Sendon,Prem Pais,Alexander Parkhomenko,Jun Zhu,Lars Wallentin +29 more